1219P Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC
Barlesi F, Garon E, Kim D, Felip E, Han J, Kim J, Ahn M, Fidler M, Gubens M, Castro G, Surmont V, Li Q, Deitz A, Lubiniecki G, Herbst R. 1219P Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC. Annals Of Oncology 2016, 27: vi422. DOI: 10.1093/annonc/mdw383.19.Peer-Reviewed Original Research